Active, not recruitingPhase 1NCT03514069

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Studying Glial tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Case Comprehensive Cancer Center
Principal Investigator
David Peereboom, MD, MD
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Intervention
ruxolitinib(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03514069 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor →

← Back to all trials